Indivior Pharmaceuticals (INDV) EPS (Weighted Average and Diluted) (2024 - 2026)

Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 3 years deep, the most recent figure standing at $0.69 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 81.58% year-over-year to $0.69; the TTM figure through Mar 2026 stood at $1.95 (up 9850.0% YoY), while the FY2025 annual figure was $1.64, up 3180.0% from the prior year.
• EPS (Weighted Average and Diluted) was $0.69 for Q1 2026 at Indivior Pharmaceuticals, down from $0.79 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.79 in Q4 2025 to a low of -$0.72 in Q2 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.26 across 3 years, with a median of $0.33 in 2025.
• Biggest YoY gain for EPS (Weighted Average and Diluted) was 393.75% in 2025; the steepest drop was 15.56% in 2025.
• A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.16 in 2024, then soared by 393.75% to $0.79 in 2025, then retreated by 12.66% to $0.69 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.69 (Q1 2026), $0.79 (Q4 2025), and $0.33 (Q3 2025), per Business Quant data.